Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Claude Barbare

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Anticancer Research|April 9, 2013
Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragmentsCorinne Godin, Sebastien Dupont, Zakaria Ezzoukhry, et al.
World Journal of Gastroenterology|January 5, 2007
Management of digestive bleeding related to portal hypertension in cirrhotic patients: A French multicenter cross-sectional practice surveyPierre Ingrand, Jerome Gournay, Pierre Bernard, et al.
Anticancer Research|March 10, 2015
Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenibCorinne Godin, Christophe Louandre, Sandra Bodeau, et al.
Gastroenterologie Clinique Et Biologique|January 2, 2008
Management practices for gastrointestinal hemorrhage related to portal hypertension in cirrhotic patients: evaluation of the impact of the Paris consensus workshopClaire Charpignon, Frédéric Oberti, Pierre Bernard, et al.
Cancer Letters|November 8, 2015
Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenibAline Houessinon, Albane Gicquel, Flora Bochereau, et al.
Molecular Cancer Research : MCR|July 22, 2010
BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinomaAntoine Galmiche, Zakaria Ezzoukhry, Catherine François, et al.
Cancer Biology & Therapy|September 10, 2009
Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multi-center French studyEric Nguyen-Khac, Isabelle Ollivier, Thomas Aparicio, et al.
Molecular Cancer|May 18, 2016
Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenibAline Houessinon, Catherine François, Chloé Sauzay, et al.
Radiology|May 1, 2019
Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II TrialBoris Guiu, Patrick Chevallier, Eric Assenat, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2009
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled studyJean-Claude Barbare, Olivier Bouché, Franck Bonnetain, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Anticancer Research|April 9, 2013
Heterogeneous sensitivity of hepatocellular carcinoma to sorafenib revealed by the short-term culture of tumor fragmentsCorinne Godin, Sebastien Dupont, Zakaria Ezzoukhry, et al.
World Journal of Gastroenterology|January 5, 2007
Management of digestive bleeding related to portal hypertension in cirrhotic patients: A French multicenter cross-sectional practice surveyPierre Ingrand, Jerome Gournay, Pierre Bernard, et al.
Anticancer Research|March 10, 2015
Biomarkers of apoptosis and necrosis in patients with hepatocellular carcinoma treated with sorafenibCorinne Godin, Christophe Louandre, Sandra Bodeau, et al.
Gastroenterologie Clinique Et Biologique|January 2, 2008
Management practices for gastrointestinal hemorrhage related to portal hypertension in cirrhotic patients: evaluation of the impact of the Paris consensus workshopClaire Charpignon, Frédéric Oberti, Pierre Bernard, et al.
Cancer Letters|November 8, 2015
Alpha-fetoprotein is a biomarker of unfolded protein response and altered proteostasis in hepatocellular carcinoma cells exposed to sorafenibAline Houessinon, Albane Gicquel, Flora Bochereau, et al.
Molecular Cancer Research : MCR|July 22, 2010
BAD, a proapoptotic member of the BCL2 family, is a potential therapeutic target in hepatocellular carcinomaAntoine Galmiche, Zakaria Ezzoukhry, Catherine François, et al.
Cancer Biology & Therapy|September 10, 2009
Somatostatin receptor scintigraphy screening in advanced hepatocarcinoma: A multi-center French studyEric Nguyen-Khac, Isabelle Ollivier, Thomas Aparicio, et al.
Molecular Cancer|May 18, 2016
Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenibAline Houessinon, Catherine François, Chloé Sauzay, et al.
Radiology|May 1, 2019
Idarubicin-loaded Beads for Chemoembolization of Hepatocellular Carcinoma: The IDASPHERE II Single-Arm Phase II TrialBoris Guiu, Patrick Chevallier, Eric Assenat, et al.
European Journal of Cancer (Oxford, England : 1990)|March 24, 2009
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled studyJean-Claude Barbare, Olivier Bouché, Franck Bonnetain, et al.
Pageof 4